Clin Osteol 2016; 21(3): 79-88

Management of ONJ in bone disease and onkology patientsReview articles

J. Jambura, L. Hauer, D. Hrušák, V. Vyskočil, L. Hostička, P. Andrle, P. Pošta, J. Genčur

Medication-related osteonecrosis of the jaw (MRONJ) is a rare but severe complication affecting patients receiving antiresorptive and/or biological therapy influencing bone metabolism. Moreover, the increasing use of these drugs and introduction of high-risk medicines increases the incidence of this condition. The therapy is sometimes very difficult, often lengthy and, so far, without clear consensus among experts. However, recent findings suggest that in the management of osteonecrosis of the jaw, better results are achie­ ved with radical surgical therapy than a conservative approach. Surgical therapy should be indicated as early, regardless of the disea­ se stage; if this way of treatment is contraindicated, the conservative approach is reasonable. The most important strategy, however, is compliance with preventive measures and interdisciplinary cooperation. In their paper, the authors provide an overview of the cur­ rent options for the diagnosis, staging and treatment of MRONJ.

Keywords: osteonecrosis ofthejaw, antiresorptive therapy, bone metabolism, diagnosis, staging, therapy

Published: December 11, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Jambura J, Hauer L, Hrušák D, Vyskočil V, Hostička L, Andrle P, et al.. Management of ONJ in bone disease and onkology patients. Osteologický bulletin. 2016;21(3):79-88.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Almazrooa SA, Woo SB. Bisphosphonate and nonbisphosphonate-associated os­ teonecrosis of the jaw: a review. J Am Dent Assoc 2009;140(7):864-875. Go to original source...
    2. Hauer L. Historie a etiologie čelistních osteonekróz. Prakt Zub Lék 2009; 57(5):71-75.
    3. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular nec­ rosis ofthejaws: a growing epidemic. J Oral Maxillofac Surg 2003;61(9):111 Go to original source...
    4. Estilo CL, Fornier M, Farooki A, Carlson D, Bohle G 3rd, Huryn JM. Osteonecrosis of the jaw related to bevacizumab. J Clin Oncol 2008;26(24): 4037 4038. Go to original source...
    5. Taylor KH, Middlefell LS, Mizen KD. Osteonecrosis of the jaws i RANK ligand therapy. Br J Oral Maxillofac Surg 2010;48(3):221-223. Go to original source...
    6. Koch FP, Walter C, Hansen T, Jager E, Wagner W. Osteo ted to sunitinib. Oral Maxillofac Surg 2011;15(1):63-66. Go to original source...
    7. Kim DW, Jung YS, Prk HS, Jung HD. Osteonecrosis of the jaw related to ev limus: a case report. Br J Oral Maxillofac Surg 2013;51(8):e302-304. Go to original source...
    8. Troeltzsch M, Woodlock T, Kriegelstein S, Steiner T, Messlinger K, Troeltzsch M. Physiology and pharmacology of nonbisphosphonate drugs impli­ cated in osteonecrosis of the jaw. J Can Dent Assoc 2012;78:c85.
    9. Hauer L, Hrušák D, Hostička L, Andrle P, Jambura J, Bisfosfonáty a dutina ústní. Stomateam 2010;10(5):5-14.
    10. Hauer L, Hrušák D, Hostička L, Andrle P, Jambura J, Pošta P. Osteonekróza listí v souvislosti s celkovou léčbou bisfosfonáty - doporučení pro praxi. LKS 2011;21(5):94-105.
    11. Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007;65(3):369-376. Go to original source...
    12. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O'Ryan F. American Association of Oral and Maxillofacial Surgeons position pa­ per on medication-related osteonecrosis of the jaw - 2014 update. J Oral Maxi fac Surg 2014;72(10):1938-1956. Go to original source...
    13. Khan AA et al. Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus. Journal of Bone and Mineral Research 2015;30(1):3-23. Go to original source...
    14. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws - 2009 update. J Oral Maxillofac Surg 2009;67 (5 Suppl):2-12. Go to original source...
    15. Stockmann P, Hinkmann FM, Lell MM, Fenner M, Vairaktaris E, Neukam FW, Nkenke E. Panoramic radiograph, computed tomography or magnetic resonance imaging. Which imaging technique should be preferred in bisphosphonate-asso­ ciated osteonecrosi 2010;14(3):311-317. Go to original source...
    16. Hansen T, Kunkel M, Springer E, Walter C, Weber A, Siegel E, Kirkpatrick CJ. Actinomycosis of the jaws - histopathological study of 45 patients shows signifi­ cant involvement in bisphosphonate-associated osteo radionecrosis. Virchows Arch 2007;451(6):1009-1017. Go to original source...
    17. Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, Nooka A, Sayegh G, Guarneri V, Desrouleaux K, Cui J, Adamus A, Gagel RF, Hortobagyi GN. Frequency and risk factors associated with osteonecrosis of the jaw in c patients treated with intravenous bisphosphonates. J Bone Miner Res 2008; 23(6):826-836. Go to original source...
    18. Lazarovici TS, Yahalom R, Taicher S, Elad S, Hardan I, Yarom N. Bisphos­ phonate related osteonecrosis of the jaws: a single-center study of 101 pat J Oral Maxillofac Surg 2009;67(4):850-855. Go to original source...
    19. Holzinger D, Seemann R, Klug C, Ewers R, Millesi G, Baumann A, Wutzl A, Long-term success of surgery in bisphosphonate-related osteonecrosis of the (BRONJs). Oral Oncol 2013;49(1):66-70. Go to original source...
    20. Stockmann P, Vairaktaris E, Wehrhan F, Seiss M, Schwarz S, Spriewald B, Neukam FW, Nkenke E. Osteotomy and primary wound closure in bisphosphona­ te-associated osteonecrosis of the jaw: a prospective clinical study with follow-up. Support Care Cancer 2010;18(4):449-460. Go to original source...
    21. Stockmann P, Burger M, von Wilmowsky C, Ebker T, Lutz R, Bauersachs A, Nkenke E, Neukam FW, Wehrhan F. The outcome after surgical therapy of bis­ phosphonate-associated osteonecrosis of the jaw-results of a clinical case series with an average follow-up of 20 months. Clin Oral Investig 2014;18(4):1299-1304. Go to original source...
    22. Carlson ER, Basile JD. The role of surgical resection in the management of b phosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2009; 67(5 Suppl):85-95. Go to original source...
    23. Assaf AT, Zrnc TA, Riecke B, Wikner J, Zustin J, Friedrich RE, Heiland M, Smeets R, Grobe A. Intraoperative efficiency of fluorescence imaging by Visually Enhanced Lesion Scope (VELscope®) in patients with bisphosphonate related osteonecrosis of the jaw (BRONJ). J Craniomaxillofac Surg 2014;42(5):e157-164. Go to original source...
    24. Voss PJ, Joshi Oshero J, Kovalova-Muller A, Veigel Merino EA, Sauerbier S, Al-Jamali J, Lemound J, Metzger MC, Schmelzeisen R. Surgical treatment of bisphosphonate-associated osteonecrosis of thejaw: technical report and follow of 21 patients. J Craniomaxillofac Surg 2012;40(8):719-725. Go to original source...
    25. Williamson RA. Surgical management of bisphosphonate induced osteonecrosis of the jaws. Int J Oral Maxillofac Surg, 2010,39(3):251-255. Go to original source...
    26. Ristow O, Otto S, Troeltzsch M, Hohlweg-Majert B, Pautke C. Treatment per­ spectives for medication-related osteonecrosis of the jaw (MRONJ). J Cranio­ maxillofac Surg 2015;43(2):290-293. Go to original source...
    27. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O'Ryan F. American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medicationrelated osteonecrosis of the jaw - 2014 update. J Oral Maxillofac Surg 2014; 72(10):1938-1956. Go to original source...
    28. Epstein MS, Ephros HD, Epstein JB. Review of current literature and implica of RANKL inhibitors for oral health care providers. Oral Surg Oral Med Oral Pathol Oral Radiol 2013;116(6):e437^42. Go to original source...
    29. Graziani F, Vescovi P, Campisi G, Favia G, Gabriele M, Gaeta GM, Gennai S, Goia F, Miccoli M, Peluso F, Scoletta M, Solazzo L, Colella G. Resective surgi­ cal approach shows a high performance in the management of advanced cases of bisphosphonate-related osteonecrosis of the jaws: a retrospective survey of 347 ses. J Oral Maxillofac Surg 2012;70(11):2501-2507. Go to original source...
    30. Otto S, Baumann S, Ehrenfeld M, Pautke C. Successful surgical management of osteonecrosis of the jaw due to RANK-ligand inhibitor treatment using fluores­ cence guided bone resection. J Craniomaxillofac Surg 2013;41(7):694-698. Go to original source...
    31. Rosa J, Pavlíková G, Ihlička V. Osteonekróza čelisti u pacient sorpční léčbu osteoporózy. Osteologický bulletin 2013;18(3):68-76.

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.